Researchers at Stanford and Berkeley Lab’s Molecular Foundry have developed virus-killing molecules called peptoids. The technology could make possible an emerging category of antiviral drugs that could treat everything from herpes and COVID-19 to the common cold.
Earlier this month, Baylor Scott & White Research Institute enrolled the first four patients in the world on Gilead’s new clinical trial involving an investigational inhaled solution of remdesivir (NCT04539262). This is Gilead’s first trial in COVID-19 patients examining the safety and efficacy of an inhaled solution of the drug in an outpatient setting. The study of an inhaled solution asks whether this mode of delivery can help reduce the amount of virus from the airways earlier.